Clinical Trial: Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Domestic Recombinant Human Follitropin (Gonal-F) for Injection for treatment of WHO Ⅱ anovulation (including polycystic ovarian syndrome [PCOS] subjects).
Detailed Summary:
Sponsor: GeneScience Pharmaceuticals Co., Ltd.
Current Primary Outcome: The efficiency reached mature follicle (the diameter of follicular ≥18mm by type-B ultrasonic) within the start period on the day of HCG day. [ Time Frame: participants will be followed within the HCG day, an expected average of 14±2 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: GeneScience Pharmaceuticals Co., Ltd.
Dates:
Date Received: January 5, 2015
Date Started: May 2008
Date Completion:
Last Updated: January 9, 2015
Last Verified: January 2015